TipRanks
Insmed (CH:IM8N)
:IM8N
Switzerland Market
IM8N
Insmed
RESEARCH TOOLSreports

Insmed (IM8N) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

IM8N Analyst Ratings

Strong Buy
20Ratings
Strong Buy
20 Buy
0 Hold
0 Sell
Based on 20 analysts giving stock ratings to
Insmed
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IM8N Stock 12 Month Forecast

Average Price Target

―
Based on 20 Wall Street analysts offering 12 month price targets for Insmed in the last 3 months. The average price target is CHF164.59 with a high forecast of CHF201.79 and a low forecast of CHF140.34. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"94":"CHF94","121":"CHF121","148":"CHF148","175":"CHF175","202":"CHF202"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":201.78718785,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF201.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":164.59401114210527,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF164.59</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140.33759155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF140.34</span>\n  </div></div>","useHTML":true}}],"tickPositions":[94,121,148,175,202],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.967,104.10701445,112.2470289,120.38704335,128.5270578,136.66707225,144.8070867,152.94710115,161.0871156,169.22713005,177.3671445,185.50715895000002,193.64717339999999,{"y":201.78718785,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.967,101.24600085708502,106.52500171417005,111.80400257125507,117.08300342834008,122.36200428542512,127.64100514251012,132.92000599959516,138.19900685668017,143.47800771376518,148.75700857085022,154.03600942793523,159.31501028502026,{"y":164.59401114210527,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.967,99.38012242692308,102.79324485384616,106.20636728076923,109.61948970769231,113.03261213461539,116.44573456153847,119.85885698846155,123.27197941538462,126.6851018423077,130.0982242692308,133.51134669615385,136.92446912307693,{"y":140.33759155,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":95.967,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.967,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.967,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.967,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.967,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.967,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.967,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.967,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.967,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.967,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.967,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.967,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.967,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF201.79Average Price TargetCHF164.59Lowest Price TargetCHF140.34
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on CH:IM8N
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF181.03
Buy
―
Reiterated
10/02/26
Insmed: Overweight Rating Reaffirmed as Brinsupri Momentum Drives Raised 2026 Guidance; Price Target Maintained at $218
Barclays Analyst forecast on CH:IM8N
Eliana Merle
Barclays
Barclays
CHF196.8→CHF171.89
Buy
―
Reiterated
09/30/26
Barclays Remains a Buy on Insmed (INSM)
J.P. Morgan Analyst forecast on CH:IM8N
Jessica Fye
J.P. Morgan
J.P. Morgan
CHF145.32
Buy
―
Reiterated
09/28/26
Wall Street Analysts Are Bullish on Top NA Picks
Goldman Sachs Analyst forecast on CH:IM8N
Andrea Newkirk
Goldman Sachs
Goldman Sachs
CHF156.12
Buy
―
Initiated
09/24/26
Wall Street Analysts Are Bullish on Top NA Picks
Mizuho Securities Analyst forecast on CH:IM8N
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
CHF161.93
Buy
―
Reiterated
09/22/26
Mizuho Securities Sticks to Its Buy Rating for Insmed (INSM)
Bank of America Securities Analyst forecast on CH:IM8N
Jason Zemansky
Bank of America Securities
Bank of America Securities
CHF177.71
Buy
―
Reiterated
09/21/26
Insmed: Buy Rating Reaffirmed on Arikayce Growth and Pipeline Upside with Price Target Maintained at $214
Roth MKM Analyst forecast on CH:IM8N
Adam Walsh
Roth MKM
Roth MKM
CHF176.04→CHF164.42
Buy
―
Reiterated
09/15/26
Roth MKM Remains a Buy on Insmed (INSM)
RBC Capital Analyst forecast on CH:IM8N
Leonid Timashev
RBC Capital
RBC Capital
CHF161.93
Buy
―
Reiterated
08/25/26
RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)
BMO Capital Analyst forecast on CH:IM8N
Conor MacKay
BMO Capital
BMO Capital
CHF159.44
Buy
―
Reiterated
08/17/26
Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Insmed (INSM)
H.C. Wainwright Analyst forecast on CH:IM8N
Andrew Fein
H.C. Wainwright
H.C. Wainwright
CHF182.69
Buy
―
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Minerva Neurosciences (NASDAQ: NERV) and Zymeworks (NASDAQ: ZYME)
Truist Financial Analyst forecast on CH:IM8N
Danielle Brill
Truist Financial
Truist Financial
CHF153.62→CHF161.93
Buy
―
Reiterated
08/10/26
Truist Financial Remains a Buy on Insmed (INSM)
Evercore ISI Analyst forecast on CH:IM8N
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
CHF132.86→CHF141.17
Buy
―
Reiterated
08/07/26
Insmed price target raised to $170 from $160 at Evercore ISIInsmed price target raised to $170 from $160 at Evercore ISI
UBS Analyst forecast on CH:IM8N
Ashwani Verma
UBS
UBS
CHF137.85→CHF142.83
Buy
―
Reiterated
08/07/26
Insmed price target raised to $172 from $166 at UBSInsmed price target raised to $172 from $166 at UBS
TD Cowen Analyst forecast on CH:IM8N
Ritu Baral
TD Cowen
TD Cowen
CHF201.79
Buy
―
Reiterated
08/06/26
Insmed (INSM): Brinsupri Outperformance and Raised Sales Guidance Support Buy Rating
Jefferies Analyst forecast on CH:IM8N
Faisal Khurshid
Jefferies
Jefferies
CHF132.86→CHF145.32
Buy
―
Reiterated
08/06/26
Insmed price target raised to $175 from $160 at JefferiesInsmed price target raised to $175 from $160 at Jefferies
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on CH:IM8N
Maxwell Skor
Morgan Stanley
Morgan Stanley
CHF181.03
Buy
―
Reiterated
10/02/26
Insmed: Overweight Rating Reaffirmed as Brinsupri Momentum Drives Raised 2026 Guidance; Price Target Maintained at $218
Barclays Analyst forecast on CH:IM8N
Eliana Merle
Barclays
Barclays
CHF196.8→CHF171.89
Buy
―
Reiterated
09/30/26
Barclays Remains a Buy on Insmed (INSM)
J.P. Morgan Analyst forecast on CH:IM8N
Jessica Fye
J.P. Morgan
J.P. Morgan
CHF145.32
Buy
―
Reiterated
09/28/26
Wall Street Analysts Are Bullish on Top NA Picks
Goldman Sachs Analyst forecast on CH:IM8N
Andrea Newkirk
Goldman Sachs
Goldman Sachs
CHF156.12
Buy
―
Initiated
09/24/26
Wall Street Analysts Are Bullish on Top NA Picks
Mizuho Securities Analyst forecast on CH:IM8N
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
CHF161.93
Buy
―
Reiterated
09/22/26
Mizuho Securities Sticks to Its Buy Rating for Insmed (INSM)
Bank of America Securities Analyst forecast on CH:IM8N
Jason Zemansky
Bank of America Securities
Bank of America Securities
CHF177.71
Buy
―
Reiterated
09/21/26
Insmed: Buy Rating Reaffirmed on Arikayce Growth and Pipeline Upside with Price Target Maintained at $214
Roth MKM Analyst forecast on CH:IM8N
Adam Walsh
Roth MKM
Roth MKM
CHF176.04→CHF164.42
Buy
―
Reiterated
09/15/26
Roth MKM Remains a Buy on Insmed (INSM)
RBC Capital Analyst forecast on CH:IM8N
Leonid Timashev
RBC Capital
RBC Capital
CHF161.93
Buy
―
Reiterated
08/25/26
RBC Capital Reaffirms Their Buy Rating on Insmed (INSM)
BMO Capital Analyst forecast on CH:IM8N
Conor MacKay
BMO Capital
BMO Capital
CHF159.44
Buy
―
Reiterated
08/17/26
Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Insmed (INSM)
H.C. Wainwright Analyst forecast on CH:IM8N
Andrew Fein
H.C. Wainwright
H.C. Wainwright
CHF182.69
Buy
―
Reiterated
08/10/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), Minerva Neurosciences (NASDAQ: NERV) and Zymeworks (NASDAQ: ZYME)
Truist Financial Analyst forecast on CH:IM8N
Danielle Brill
Truist Financial
Truist Financial
CHF153.62→CHF161.93
Buy
―
Reiterated
08/10/26
Truist Financial Remains a Buy on Insmed (INSM)
Evercore ISI Analyst forecast on CH:IM8N
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
CHF132.86→CHF141.17
Buy
―
Reiterated
08/07/26
Insmed price target raised to $170 from $160 at Evercore ISIInsmed price target raised to $170 from $160 at Evercore ISI
UBS Analyst forecast on CH:IM8N
Ashwani Verma
UBS
UBS
CHF137.85→CHF142.83
Buy
―
Reiterated
08/07/26
Insmed price target raised to $172 from $166 at UBSInsmed price target raised to $172 from $166 at UBS
TD Cowen Analyst forecast on CH:IM8N
Ritu Baral
TD Cowen
TD Cowen
CHF201.79
Buy
―
Reiterated
08/06/26
Insmed (INSM): Brinsupri Outperformance and Raised Sales Guidance Support Buy Rating
Jefferies Analyst forecast on CH:IM8N
Faisal Khurshid
Jefferies
Jefferies
CHF132.86→CHF145.32
Buy
―
Reiterated
08/06/26
Insmed price target raised to $175 from $160 at JefferiesInsmed price target raised to $175 from $160 at Jefferies
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ZVRAZevra Therapeutics
DFTXDefinium Therapeutics
HITIHigh Tide
DNLIDenali Therapeutics
MDWDMediwound
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Insmed

3 Months
Jessica FyeJ.P. Morgan
Success Rate
16/22 ratings generated profit
73%
Average Return
+21.48%
Copying Jessica Fye's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +21.48% per trade.
1 Year
Tiago FauthRaymond James
Success Rate
15/17 ratings generated profit
88%
Average Return
+83.38%
Copying Tiago Fauth's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +83.38% per trade.
2 Years
Tiago FauthRaymond James
Success Rate
15/17 ratings generated profit
88%
Average Return
+183.43%
Copying Tiago Fauth's trades and holding each position for 2 Years would result in 88.24% of your transactions generating a profit, with an average return of +183.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IM8N Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
33
51
46
42
22
Buy
19
8
14
15
11
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
52
59
60
57
33
In the current month, IM8N has received 33 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IM8N average Analyst price target in the past 3 months is 164.59.
Each month's total comprises the sum of three months' worth of ratings.

IM8N Financial Forecast

IM8N Earnings Forecast

Next quarter’s earnings estimate for IM8N is -CHF0.32 with a range of -CHF0.75 to CHF0.03. The previous quarter’s EPS was -CHF0.05. IM8N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IM8N has Performed in-line its overall industry.
Next quarter’s earnings estimate for IM8N is -CHF0.32 with a range of -CHF0.75 to CHF0.03. The previous quarter’s EPS was -CHF0.05. IM8N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year IM8N has Performed in-line its overall industry.

IM8N Sales Forecast

Next quarter’s sales forecast for IM8N is CHF415.44M with a range of CHF379.00M to CHF434.63M. The previous quarter’s sales results were CHF352.86M. IM8N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IM8N has Performed in-line its overall industry.
Next quarter’s sales forecast for IM8N is CHF415.44M with a range of CHF379.00M to CHF434.63M. The previous quarter’s sales results were CHF352.86M. IM8N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year IM8N has Performed in-line its overall industry.

IM8N Stock Forecast FAQ

What is CH:IM8N’s average 12-month price target, according to analysts?
Based on analyst ratings, Insmed’s 12-month average price target is 164.59.
    What is CH:IM8N’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:IM8N, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Insmed a Buy, Sell or Hold?
        Insmed has a consensus rating of Strong Buy, which is based on 20 buy ratings, 0 hold ratings and 0 sell ratings.
          What is Insmed’s share price target?
          The average share price target for Insmed is 164.59. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF201.79 ,and the lowest forecast is CHF140.34. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Insmed?
            Insmed’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.
              How can I buy shares of Insmed?
              To buy shares of CH:IM8N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.